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ORIGINAL RESEARCH
Gelatin Methacryloyl Bioadhesive Improves 
Survival and Reduces Scar Burden in a 
Mouse Model of Myocardial Infarction
Leon M. Ptaszek, MD, PhD*; Roberto Portillo Lara, PhD*; Ehsan Shirzaei Sani, BS; Chunyang Xiao, PhD;  
Jason Roh, MD; Xuejing Yu, MD, PhD; Pablo A. Ledesma, MD; Chu Hsiang Yu, PhD; Nasim Annabi, PhD†; 
Jeremy N. Ruskin, MD†
BACKGROUND: Delivery of hydrogels to the heart is a promising strategy for mitigating the detrimental impact of myocardial 
infarction (MI). Challenges associated with the in vivo delivery of currently available hydrogels have limited clinical translation of 
this technology. Gelatin methacryloyl (GelMA) bioadhesive hydrogel could address many of the limitations of available hydro-
gels. The goal of this proof- of- concept study was to evaluate the cardioprotective potential of GelMA in a mouse model of MI.
METHODS AND RESULTS: The physical properties of GelMA bioadhesive hydrogel were optimized in vitro. Impact of GelMA 
bioadhesive hydrogel on post- MI recovery was then assessed in vivo. In 20 mice, GelMA bioadhesive hydrogel was applied 
to the epicardial surface of the heart at the time of experimental MI. An additional 20 mice underwent MI but received no 
GelMA bioadhesive hydrogel. Survival rates were compared for GelMA- treated and untreated mice. Left ventricular function 
was assessed 3 weeks after experimental MI with transthoracic echocardiography. Left ventricular scar burden was meas-
ured with postmortem morphometric analysis. Survival rates at 3 weeks post- MI were 89% for GelMA- treated mice and 50% 
for untreated mice (P=0.011). Left ventricular contractile function was better in GelMA- treated than untreated mice (fractional 
shortening 37% versus 26%, P<0.001). Average scar burden in GelMA- treated mice was lower than in untreated mice (6% 
versus 22%, P=0.017).
CONCLUSIONS: Epicardial GelMA bioadhesive application at the time of experimental MI was performed safely and was associ-
ated with significantly improved post- MI survival compared with control animals. In addition, GelMA treatment was associated 
with significantly better preservation of left ventricular function and reduced scar burden.
Key Words: Bioadhesive ■ myocardial fibrosis ■ myocardial infarction
Currently available pharmacological and mechani-cal treatments for acute myocardial infarction (MI) are limited in their ability to prevent cell injury and 
death and associated inflammation.1–5 Consequently, 
clinically significant myocardial fibrosis can be found 
even in patients who receive state- of- the- art treat-
ment for acute MI.6–8 Fibrosis- related disruption of 
myocardial architecture is responsible for the most 
common clinical sequelae of MI, including left ven-
tricular (LV) contractile dysfunction and susceptibility 
to life- threatening ventricular arrhythmias and sudden 
cardiac death.9,10
Hydrogels are 3- dimensional (3D) hydrophilic 
polymer networks capable of absorbing large 
amounts of water to form a suitable environment for 
cellular growth.11,12 Direct application of hydrogels to 
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the heart has been proposed as an adjunct to exist-
ing treatments for acute MI, with the goal of reduc-
ing myocardial fibrosis and adverse LV remodeling 
after MI.13 Hydrogels could potentially modulate the 
post- MI injury response by providing biomimetic me-
chanical support to the infarcted, weakened tissue. 
They can also serve as vehicles for the delivery of 
therapies aimed at myocardial preservation and re-
generation, including cells, proteins, nucleotides, and 
small molecules.14–18 Recent advances in hydrogel 
polymerization chemistry have produced several for-
mulations that can be efficiently crosslinked in vivo. 
These hydrogels can be applied to target organs in 
liquid form and crosslinked into solid form within the 
target organ. Application of hydrogel in liquid form 
could facilitate the development of less invasive de-
livery techniques than are required for delivery of 
pre–crosslinked (solid) hydrogels.17,19
Controlled polymerization of liquid hydrogel pre-
cursors in vivo is potentially challenging.20 Chemical 
and enzymatic crosslinking strategies can lead to 
uncontrolled polymerization, which can compromise 
both the mechanical integrity of the scaffold and its 
ability to adhere to the target tissue.21 Incomplete po-
lymerization of hydrogel can also lead to leakage of 
unreacted components of the precursor solution into 
nontarget organs. Adjustment of the chemical/en-
zymatic polymerization conditions to produce more 
rapid polymerization may offset this risk, but may 
then result in other problems, such as polymerization 
within the equipment used to deliver the hydrogel. 
In addition, rapid polymerization can lead to unde-
sirable mechanical properties, undesirable drug re-
lease kinetics, or both. Complete polymerization and 
tissue adhesion are particularly important in the con-
text of the heart, as cardiac motion can lead to de-
tachment and migration of incompletely polymerized 
hydrogel precursor.22 Photoinitiation has emerged as 
an attractive alternative to chemical/enzymatic po-
lymerization because it provides precise temporal 
and spatial control over the crosslinking process.23,24 
In addition, this approach allows for facile adjustment 
of the physical properties of the hydrogel (eg, elastic-
ity and stiffness) to match those of the target tissue. 
Cross linking of hydrogels through exposure to ultra-
violet light has been described.21 Although ultraviolet 
light has been previously shown to induce efficient 
cross linking of hydrogels in vivo, the clinical use of 
ultraviolet light has been limited because of the DNA 
damage associated with ultraviolet light exposure, 
and the associated increase in the risk of cancer.25
The hydrogel system described in this study is 
based on the naturally derived biopolymer, gelatin, 
which can be modified to form photo–crosslinkable 
gelatin methacryloyl (GelMA). Gelatin was selected as 
the foundation of this system because it is highly bio-
compatible and biodegradable. In addition, through 
photopolymerization, we can adjust the rate of GelMA 
degradation so that GelMA is present during the time 
window needed for post-infarct injury repair, typically 
within 2 weeks of the initial event. GelMA hydrogel has 
been optimized to be photo–crosslinked through ex-
posure to visible light (450–550 nm).26–28 Visible light 
cross linking has been shown to retain the advantages 
of ultraviolet- based crosslinking (strong adhesion to 
tissue, rapid and controlled polymerization), with-
out the adverse effects associated with exposure to 
ultraviolet light.29 In addition, visible- spectrum light 
provides comparatively deeper tissue penetration 
than ultraviolet light, with lower energy.30 The physical 
CLINICAL PERSPECTIVE
What Is New?
• Gelatin methacryloyl (GelMA) bioadhesive hydro-
gel is nontoxic, biocompatible, and biodegradable.
• GelMA bioadhesive hydrogel can be delivered 
to the epicardial surface of the heart in liquid 
precursor form and polymerized in situ using 
visible-spectrum light, and the elastic properties 
of GelMA can be “tuned” to match the elasticity 
of native heart tissue.
• Application of GelMA bioadhesive hydrogel to the 
surface of a mouse heart at the time of experi-
mental myocardial infarction was safe and was 
associated with reductions in post–myocardial 
infarction scar formation and mortality as well as 
preservation of left ventricular systolic function.
What Are the Clinical Applications?
• Epicardial application of GelMA bioadhesive hy-
drogel is safe and has the potential to reduce 
scar formation and preserve ventricular function 
in the setting of acute ischemic injury.
• GelMA bioadhesive hydrogel may serve as 
a biocompatible, biodegradable, sustained-
release platform for the delivery of therapeutic 
agents to the heart.
Nonstandard Abbreviations and Acronyms
CD cluster of differentiation
CF cardiac fibroblast
DPBS Dulbecco's phosphate-buffered saline
GelMA gelatin methacryloyl
LV left ventricular
MI myocardial infarction
TTE transthoracic echocardiography
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properties of GelMA bioadhesive, such as elastic mod-
ulus and in vivo half- life, can be adjusted through 
changes in the concentration of precursors and the 
duration of photo–crosslinking.26 Together, these fea-
tures  enhance the suitability of this visible light photo– 
cross linking strategy for clinical applications.
The GelMA hydrogel system relies on the use of 
eosin Y as a chemical photoinitiator. Although sev-
eral photoinitiators have been used with visible light- 
activated systems, eosin Y is the only one that has been 
approved by the US Food and Drug Administration for 
clinical use.31 Moreover, the irradiation times required 
to achieve polymerization using eosin Y are shorter 
than other photoinitiator systems. This increases the 
efficiency of crosslinking and minimizes the risk of 
potential leakage of unreacted hydrogel precursor. 
Shorter irradiation time may also enhance the viability 
of cells incorporated within the hydrogel.32
This proof- of- concept study was designed to as-
sess the cardioprotective impact of visible light cross- 
linked GelMA bioadhesive applied to the epicardial 
surface of the heart at the time of experimental MI 
in mice. Epicardial application was used to avoid the 
risks of delivery by intramyocardial injection, includ-
ing cardiac injury and systemic spread of hydrogel. In 
this study, the bioadhesive precursors were delivered 
to the epicardial surface in liquid form immediately 
after creation of an experimental MI. GelMA prepoly-
mer was photo-crosslinked immediately after epicar-
dial application with visible- spectrum light. Several 
post- MI outcomes were measured, including mortal-
ity rate, LV contractile function, and LV scar burden.
METHODS
Data will be made available at the Harvard Dataverse 
and will be accessible via the Dataverse site.
Synthesis and Chemical Characterization 
of GelMA Bioadhesives
GelMA hydrogel was synthesized as described pre-
viously.33 Gelatin from porcine skin (Sigma- Aldrich) 
was dissolved in Dulbecco's phosphate-buffered 
saline (DPBS; Gibco) to a final concentration of 
10 g/100 mL. A total of 8 mL of methacrylic anhydride 
(Sigma- Aldrich) was then added to react with gelatin 
for 3 hours at 60°C. This solution was then diluted 
3- fold with DPBS, dialyzed against distilled water for 
7  days, and lyophilized. The bioadhesive precursor 
solution (10% (w/v)) was then prepared in DPBS con-
taining 1.88% (w/v) triethanolamine (Sigma- Aldrich) 
and 1.25% (w/v) of N- vinylcaprolactam (Sigma- 
Aldrich). Eosin Y was dissolved separately in DPBS to 
produce a 0.5 mmol/L solution. The final bioadhesive 
hydrogel was prepared by using 10% (w/v) GelMA, 
1.5% triethanolamine, 1% N- vinylcaprolactam, and 
0.1  mmol/L eosin Y. The bioadhesive precursor 
was warmed up to 37°C and was then exposed to 
blue- green light (100  mW/cm2; xenon source from 
Genzyme Biosurgery) in the 450- to 550- nm range 
for 1, 2, and 4 minutes to form crosslinked hydrogels. 
The distance between the light source and the tar-
get was 1 cm for all experiments. The formation of 
the crosslinked hydrogel network and estimation of 
the degree of cross- linking were determined through 
proton nuclear magnetic resonance (HNMR) analy-
sis using a Varian Inova 500 nuclear magnetic reso-
nance spectrometer, as described previously.34
In Vitro Swelling and Degradation of 
GelMA Bioadhesive
To determine GelMA bioadhesive water uptake (swelling), 
the hydrogels were synthesized and their weights were 
measured after incubation in DPBS at 37°C for 48 hours. 
The hydrogels were then lyophilized, and the weights 
were remeasured. The swelling ratio was defined as the 
hydrated weight divided by the dry weight (n=6).
To determine the in vitro degradation rate, the hy-
drogels were freeze dried, weighed, and incubated 
in 1  mL of DPBS at 37°C for 14  days. The samples 
(retrieved at days 1, 4, 7, 10, and 14 post-incubation) 
were freeze dried and weighed. The degradation ratio 
of the hydrogels was calculated by dividing the initial 
dry weight by the dry weight after incubation (n=6).
Mechanical Characterization of GelMA 
Bioadhesive
The elastic moduli of the hydrogels were determined 
as described previously.35 Hydrogels were synthesized 
as described above using rectangular (14×5×1 mm) 
molds. Uniaxial tensile tests were performed on hydro-
gels placed between 2 pieces of double- sided tape 
within the tension grips of an Instron 5542 mechani-
cal tester (n=4). Hydrogels were extended at a rate of 
1 mm/min until failure. The stress- strain curves were 
used to calculate the elastic moduli.
Burst Pressure and Adhesive Strength of 
GelMA Bioadhesive
Burst pressure was determined on the basis of pro-
cedures described previously (n=4).36 Explanted rat 
hearts were used for burst pressure and adhesion 
tests. The LV was punctured and sealed with either 
the GelMA bioadhesive or a commercially available, 
polyethylene glycol–based sealant (Coseal; Baxter). A 
small catheter, connected on one end to a syringe 
pump with a pressure sensor, was introduced into the 
LV. Air was injected into the LV at 0.5 mL/s until rup-
ture. Pressure at the time of LV rupture was recorded.
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The adhesive strength of the hydrogels was deter-
mined on the basis of a modified American Society for 
Testing and Materials F2458- 05 standard (n=4).34 Rat 
hearts were washed, and the blood vessels and the 
atria were removed. The ventricles were then cut into 
sections (1×1 cm) and immersed in DPBS. The samples 
were then glued onto glass slides and joined together 
using either GelMA bioadhesive or Coseal. Samples 
(n=6) were stretched at a rate of 1 mm/min. Adhesive 
strength was measured at the point of tearing.
Scanning Electron Microscopy 
GelMA bioadhesives were polymerized on the surface 
of explanted rat hearts, as described above, to visualize 
the interface between the tissue and the scaffold. The 
samples were then lyophilized, coated, and imaged with 
a Hitachi S 4800 Scanning Electron Microscope (SEM), 
as described previously.34,35
In Vitro Cytocompatibility of GelMA 
Bioadhesives
Cytocompatibility of GelMA bioadhesive was evaluated 
through 3D encapsulation of freshly isolated rat car-
diomyocytes (CMs) and cardiac fibroblasts (CFs) at a 
ratio of 2:1 (CMs:CFs), within the hydrogel, as described 
previously.35 CMs and CFs were isolated from rat heart 
on the basis of the procedures explained in our previ-
ous studies.37–39 The cells were then encapsulated at 
1.8×107/mL density inside the hydrogel, as described 
previously.26,39 Cell viability within the hydrogel was 
evaluated using a commercial live/dead kit (Invitrogen) 
and fluorescent staining against F- actin/cell nuclei and 
sarcomeric α-actinin, as described previously.26,39
Experimental MI
In vivo experiments were conducted on 40 C57BL6 
mice (Charles River Laboratories) at ≈12 to 15 weeks 
of age. The study protocol was reviewed and approved 
by the Subcommittee for Research Animal Care at 
the Massachusetts General Hospital, according to the 
American Association of Laboratory Animal Care stand-
ards for proper research animal care. Animals were 
brought to the procedure suite, general anesthesia was 
induced, and endotracheal intubation was performed. 
Vital signs were monitored continuously. After intuba-
tion, MIs were created in the following manner. The 
heart was exposed through a left anterior thoracotomy. 
The pericardial sac was opened, and the anterior inter-
ventricular artery was visualized. A 6.0 Prolene suture 
(Ethicon) was used to ligate this vessel at its midportion, 
one half of the distance between the base and the apex 
of the heart. Blanching of the affected tissue (distal seg-
ment of the anterior wall) was visualized in all animals. 
The thoracotomy was then closed, and the animal was 
monitored until it recovered from anesthesia.
Bioadhesive Application and  
Photo–Crosslinking
Immediately after ligation of the anterior interventricular 
artery, ≈5 μL of the liquid bioadhesive precursor was 
placed on the epicardial surface of the affected myo-
cardium in 20 mice. Hydrogel precursor was imme-
diately exposed to light for 4 minutes. Twenty control 
mice received no additional intervention at the time of 
experimental MI.
Echocardiography
M- mode transthoracic echocardiography (TTE) was 
performed on all mice ≈3 weeks after experimental MI 
(Vivid E90; General Electric). All TTEs were performed 
on conscious mice. LV wall thickness and chamber di-
mensions were measured offline using EchoPACS soft-
ware (GE Healthcare, version 201). Fractional shortening 
of the LV was calculated using the following formula: 
fractional shortening=[(LV end- diastolic diameter−LV 
end- systolic diameter)/LV end- diastolic diameter]×100.
Morphometric Analysis to Assess 
Myocardial Scar Burden
Mouse hearts were explanted postmortem, fixed in 4% 
formalin solution, and embedded in paraffin blocks. 
Short- axis sections of the ventricles were created and 
then stained with Masson’s trichrome. For each heart, 
5 equally spaced sections were used to calculate fibro-
sis ratio, as described previously.40,41
Sample Size Calculation
The primary end point of the study was reduction in 
LV scar burden associated with GelMA treatment, 
as observed at the end of the prescribed postinfarct 
survival period. The estimated likelihood of success-
fully observing a difference in LV function between 
GelMA- treated and untreated mice was 50%. This 
estimation was based on our prior experience with 
pharmacologic, antifibrotic interventions in this mouse 
infarct model (Jason Roh MD (JR) and Chunyang Xiao 
PHD (CX), unpublished data, 2016). On the basis of 
this assumption, 6 iterations (in each study group) 
were required to achieve a 98% likelihood of making a 
successful observation. The estimated likelihood that 
a mouse survived the procedure and the postinfarct 
survival period was estimated to be ≈33%, thus in-
creasing the total number of mice in each group to 18. 
Estimation of survival was also based on our prior ex-
perience with the model, in which intraprocedural mor-
tality ranged between 5% to 10% and postprocedural 
mortality ranged between 30% and 50% (Jason Roh 
MD (JR) and Chunyang Xiao PHD (CX), unpublished 
data, 2016). To accommodate unexpected issues, a 
total sample size of 20 (for each group) was selected.
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Statistical Analysis
One- way ANOVA was used to assess in vitro swell-
ing and degradation of GelMA. Tukey’s multiple 
comparisons test was used to assess the elas-
tic modulus of GelMA produced with different 
crosslinking times. All pairwise comparisons of 
Figure 1. Synthesis and in vitro characterization of gelatin methacryloyl (GelMA) bioadhesive hydrogel.
A, Schematic of the synthesis and in vitro photo–crosslinking strategy of the bioadhesive hydrogel. B, 1H nuclear magnetic resonance 
(500 MHz; dimethyl sulfoxide (DMSO)- d6) spectra of GelMA precursor and crosslinked GelMA bioadhesive hydrogel. C, Elastic moduli of 
GelMA bioadhesive hydrogel produced with 10% (w/v) total polymer concentrations at different visible light exposure times, compared 
with native myocardium (n=4). In vitro degradation (D) and swelling ratios (E) of GelMA hydrogel (n=4). F, Representative images of (i) 
live/dead assay, and fluorescent staining against (ii) F- actin/4′, 6- diamidino- 2- phenylindole (DAPI) and (iii) sarcomeric α- actinin using 
3- dimensional (3D) encapsulated neonatal rat cardiomyocytes and cardiac fibroblasts inside the hydrogel at day 7 post-encapsulation. 
Data are shown as mean±SD. P values were determined by 1- way ANOVA, followed by Tukey’s multiple comparisons test for C.
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intraoperative and post- MI mortality were per-
formed with a χ2 test. Differences in LV function (as 
measured by TTE) and scar burden (as measured 
by morphometric analysis) were compared with 
2- sample T tests. All means are expressed with SD. 
Results are displayed using the Graphpad software 
package.
RESULTS
Visible light crosslinking generated a 3D hydrogel 
network (Figure  1A). Successful crosslinking was 
confirmed through HNMR analysis. The success-
ful crosslinking of GelMA hydrogels via exposure 
to visible light was confirmed by the disappearance 
of the peaks at δ=5.3 and 5.7  ppm on the spec-
tra of the crosslinked hydrogel. These correspond 
to the methacrylated groups (−C=CH2) on GelMA 
(Figure  1B). The degree of crosslinking was deter-
mined by measuring the change in the integrated 
areas under the peaks corresponding to un–cross- 
linked and crosslinked hydrogel. This comparison 
revealed that the degree of GelMA crosslinking was 
92.9±2.24% after 4  minutes of exposure to visible 
light.
Physical Characterization of GelMA 
Bioadhesives
Mechanical properties of bioadhesives formed using 
different crosslinking times (1, 2, and 4 minutes) were 
evaluated. In addition, the mechanical properties of 
rat heart were measured and compared with syn-
thesized hydrogels (Figure 1C). Rat hearts were used 
because mouse hearts were too small for this pur-
pose. Hydrogels synthesized with a final concentra-
tion of 10% (w/v) GelMA and photo–crosslinked with 
4 minutes of visible light exposure exhibited an elastic 
modulus not significantly different from that of native 
rat myocardium (≈60 kPa, Figure 1C).42 After 14 days 
of incubation, GelMA hydrogels exhibited a degrada-
tion ratio of 5.7±0.2% (Figure 1D), as well as a swelling 
ratio of 50.1±2.1% at 48 hours after incubation in DPBS 
(Figure 1E).
In Vitro 3D Cell Encapsulation in GelMA 
Bioadhesive
GelMA bioadhesives supported the growth and 
proliferation of 3D encapsulated CMs/CFs in vitro 
(Figure 1F). Viability of CMs/CFs in GelMA remained 
>90% up to 7 days post-encapsulation (Figure 1F- i). 
Fluorescent F- actin staining revealed that the cells 
could efficiently attach and spread across the bio-
adhesive scaffold (Figure  1F- ii). In addition, immu-
nofluorescent staining revealed that GelMA could 
preserve the cardiac phenotype of 3D encapsulated 
CMs, as demonstrated by positive sarcomeric 
α- actinin expression 7  days after encapsulation 
(Figure 1F- iii).
Ex Vivo Burst Pressure and Adhesive 
Strength of GelMA Bioadhesive
The burst pressure of the GelMA bioadhesive 
(11.7±1.7  kPa) was significantly higher than that 
of Coseal (6.7±1.7  kPa). Burst pressures for both 
GelMA and Coseal were lower than intact heart 
burst pressure (30.0±2.3 kPa, Figure 2A). Adhesive 
strength was significantly higher for GelMA 
(21.2±3.8  kPa) than for Coseal (11.1±1.8  kPa, 
Figure  2B). The adhesiveness of GelMA hydro-
gel to the native myocardium was confirmed with 
SEM imaging of the hydrogel/tissue interface 
(Figure  2C). SEM images revealed the establish-
ment of mechanical bonding between the bioad-
hesive scaffold and the tissue.
Effect of GelMA on Survival After 
Experimental MI
Experimental MI was generated by permanent 
 ligation of the anterior interventricular artery in 
40 mice (Figure  3A). In 20 of these mice, liquid 
GelMA precursor was applied to the epicardial 
surface of the affected area of the anterior wall 
of the LV, and 20 control mice were untreated 
at the time of MI. The GelMA precursor solution 
was photo–crosslinked by application of visible- 
spectrum light (Figure  3B). Intraprocedural mor-
tality was 2 of 20 (10%) in both GelMA- treated 
and untreated mice (Table  1). The post- MI sur-
vival rate at 3  weeks was 89% among GelMA- 
treated mice and 50% among untreated control 
mice (Table 1, P=0.011). For all mice that did not 
survive the 3- week observation period, aver-
age post- MI survival was 4±2 days. Postmortem 
analysis was performed on all mice that did not 
survive the prespecified, 3- week end point. In all 
such cases, the postmortem analysis revealed 
evidence of LV myocardial rupture in the infarct 
territory with hemothorax (Figure 3C).
Effect of GelMA on LV Function After 
Experimental MI
TTE was performed in all surviving animals 3 weeks 
after experimental MI. Thickness of the anterior 
wall of the LV was measured at the midventri-
cle for all animals, because this corresponded to 
the location of the infarcts. TTE analysis revealed 
that the average thickness of the anterior wall of 
the LV was significantly lower in untreated mice 
compared with GelMA- treated mice (0.58 versus 
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0.86  mm, P<0.001; Table  2). Posterior wall thick-
ness was not significantly different between the 
untreated and GelMA- treated mice (0.85 versus 
0.89  mm, P=0.419). Representative images of the 
echocardiograms from which these measurements 
were obtained are shown in Figure 4. The average 
LV end- diastolic diameter was not significantly dif-
ferent between the GelMA- treated and untreated 
mice; however, contractile function was signifi-
cantly different between the 2 groups. Average 
Figure 2. In vitro characterization of burst pressure and adhesive strength of gelatin methacryloyl (GelMA) bioadhesive 
hydrogel.
A, Burst pressure test on explanted rat hearts treated with GelMA bioadhesive (n=6) and the commercially available sealant Coseal 
(n=6). (i) Schematic of the modified standard test method for burst pressure, (ii) representative images of rat hearts before and after 
applying air pressure, and (iii) average burst pressure of GelMA hydrogels (10% [w/v]) compared with Coseal and a pristine heart. B, 
Wound closure test to measure the adhesive strength on isolated rat hearts treated with GelMA bioadhesive (n=6) and Coseal (n=6). (i) 
Schematic of the modified standard test method for wound closure, (ii) representative images of the wound closure test on samples 
from rat ventricles using GelMA and Coseal, and (iii) adhesive strength of GelMA hydrogels (10% [w/v]) compared with Coseal. C, 
Representative scanning electron micrographs from the interface between the ventricular myocardium and the GelMA hydrogels. Data 
are shown as mean±SD. P values were determined by 1- way ANOVA, followed by Tukey’s multiple comparisons test, for A and B. LV 
indicates left ventricle.
A
B
C
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fractional shortening was significantly higher in 
GelMA- treated mice compared with untreated mice 
(37% versus 26%, P<0.001).
Effect of GelMA Bioadhesive on LV Scar 
Burden After Experimental MI
Morphometric analysis was performed on Masson’s 
trichrome- stained sections of the LV. Average trans-
mural scar volume was expressed as a percentage of 
the total volume of LV myocardium. In GelMA- treated 
mice, the average scar volume was significantly 
smaller than the average scar volume in untreated 
mice (6±9% versus 22±10%, P=0.017; Figure  5A). 
Reduced LV scar burden in GelMA- treated mice was 
also apparent on visual inspection of stained sections 
(Figure 5B).
Effect of GelMA on Cellular Architecture 
of LV After Experimental MI
Immunofluorescent staining was performed to iden-
tify changes in cellular architecture associated with 
experimental MI. Differences between GelMA- treated 
and untreated mice were analyzed. In mice treated 
with GelMA, the expression of CM- associated markers 
sarcomeric α- actinin, cardiac troponin I, and connexin 
43 was maintained within the infarcted area of the LV. 
A representative comparison is displayed in Figure 6A 
through 6C. This is consistent with preservation of 
Figure  3. Experimental myocardial infarction (MI) and 
gelatin methacryloyl (GelMA) photo–crosslinking in situ.
A, View of the anterior wall of the left ventricle (LV) through a 
surgical thoracotomy. Placement of the suture ligation of the 
anterior interventricular artery is visible. The myocardium distal to 
the suture is blanched, consistent with ischemic injury. B, View of 
the anterior wall of the LV through a surgical thoracotomy. Suture 
ligation of the anterior interventricular artery can be seen as visible 
light is shone on the anterior LV wall immediately after the GelMA 
liquid precursor was applied to the area of injury in the anterior 
wall distal to the suture. C, Representative image of postmortem 
gross pathological characteristics in animals that did not survive 
the 3- week observation period after MI. An anterior view of the 
thoracic cavity is displayed. Location of the suture ligation on the 
anterior wall of the heart is visible, as is the region of post- MI injury. 
Presence of blood in the chest cavity is visible adjacent to the heart.
Table 1. Intraoperative and Postoperative Survival for 
Experimental MI Procedures
Variable Untreated GelMA Treated P Value
No. of 
experimental MIs
20 20 …
Intraoperative 
mortality
2/20 (10) 2/20 (10) 1
Survival 3 wk 
after MI
9/18 (50) 16/18 (89) 0.011
Data are given as number/total (percentage), unless otherwise indicated. 
GelMA indicates gelatin methacryloyl; and MI, myocardial infarction.
Table 2. Measurement of LV Size, Wall Thickness, and 
Contractile Function With TTE 3 Weeks After Experimental 
MI
Variable 
Untreated 
(N=9)
GelMA 
Treated 
(N=15)
P 
Value
Anterior wall 
thickness, mm
0.58±0.13 0.86±0.11 <0.001
Posterior wall 
thickness, mm
0.85±0.17 0.89±0.11 0.419
LV end- diastolic 
diameter, mm
4.09±1.22 3.86±0.36 0.465
LV end- systolic 
diameter, mm
3.05±1.08 2.43±0.34 0.034
Fractional 
shortening, %
26±5 37±4 <0.001
All data presented as mean±SD. GelMA indicates gelatin methacryloyl; 
LV, left ventricular; MI, myocardial infarction; and TTE, transthoracic 
echocardiography.
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CMs within the infarcted territory for GelMA- treated 
mice. The expression of the endothelial marker 
CD31 was also observed at the site of MI in GelMA- 
treated mice, corresponding to improved vasculari-
zation as compared with untreated mice (Figure 6D). 
Immunofluorescent staining was also performed 
against surface markers for T cells (CD3) and macro-
phages (CD68) to assess inflammation in the infarcted 
territory. Expression of CD3 was not clearly different 
in untreated and GelMA- treated mice. A representative 
example is displayed in Figure 6E. Staining for CD68 
was more distinct in untreated mice than in GelMA- 
treated mice (representative example in Figure 6F). This 
is consistent with reduction in MI- related inflammation 
in GelMA- treated mice. Together, staining for CMs, 
vascular endothelial cells, T cells, and macrophages 
indicates that GelMA hydrogel produced a reduction 
in the architectural disruption in myocardium without 
producing inflammation.
DISCUSSION
Development of a therapeutic hydrogel that is ca-
pable of adhering to a beating heart in vivo without 
causing toxic adverse effects presents multiple chal-
lenges.43,44 Previously reported hydrogels and adhe-
sives all possess limitations that limit their potential 
for use as therapeutic agents. For example, synthetic 
cyanoacrylate- based adhesives can be applied as liq-
uid precursors and effectively crosslinked to selected 
tissues, but are too toxic for safe use on internal or-
gans.45,46 In addition, cyanoacrylate glues are more 
rigid than cardiac tissue, and may disrupt contraction 
and promote rupture.47
As distinct from cyanoacrylate- based adhesives, 
hydrogels based on naturally occurring biological mol-
ecules are generally nontoxic. For example, several 
fibrin- based adhesives have been shown to be bio-
compatible. The elasticity of fibrin- based adhesives is 
Figure 4. Transthoracic echocardiography after myocardial infarction.
M- mode echocardiograms in representative untreated (top) and gelatin methacryloyl (GelMA)–treated 
(bottom) mouse hearts. Measurement of anterior left ventricular wall thickness denoted by the location 
of the red arrow in each panel.
Untreated mouse 
Anterior wall thickness 0.67 mm 
GelMA-treated mouse 
Anterior wall thickness 0.95 mm 
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also closer to that of cardiac tissue than cyanoacry-
lates. Unfortunately, fibrin- based glues exhibit low ad-
hesion to tissue, particularly when the tissue is wet.48,49 
Suboptimal tissue adhesion can lead to mechanically 
unstable hydrogel scaffolds that may detach from the 
heart during contraction. A gelatin- based sealant that 
exhibits better bonding to tissue has been described, 
but use of this sealant in the heart is limited by low 
elastic modulus and cytotoxicity.49
Photo–crosslinkable hydrogels have also been cre-
ated from chemically modified biomolecules with the 
goal of improving tissue adhesiveness while retaining 
the biocompatibility and elasticity of naturally occurring 
biopolymers. These hydrogels can be delivered to tis-
sue in liquid precursor form, with photo–crosslinking 
into solid form in situ. Application of previously reported 
photo–crosslinkable, adhesive hydrogels to the heart is 
limited by potentially dangerous adverse effects of the 
photo–cross linking reaction. For example, a recently 
described silk fibroin gel is a nontoxic, elastic hydrogel 
based on naturally occurring silk fiber.50 Although silk 
fibroin is fully biocompatible and biodegradable, it re-
quires γ rays for photo–cross linking. Delivery of liquid 
precursor to the target tissue with in vivo cross- linking 
Figure  5. Post–myocardial infarction scar burden in gelatin methacryloyl (GelMA)–treated vs 
untreated mice.
A, Box plots representing the percentage of transmural left ventricular (LV) fibrosis in GelMA- treated 
and untreated mice. The box limits represent the first and third quartiles. The center line within each box 
represents the median value. Whiskers represent the most extreme data points within the 1.5× interquartile 
range. B, Representative series of short- axis Masson’s trichrome- stained sections of the LV taken from 
untreated and GelMA- treated mice that survived the 3- week monitoring period. Viable myocardium is 
stained pink, and collagen (scar) is stained blue.
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is therefore associated with an unacceptably high risk 
of radiation- associated injury.51 Other photo–crosslink-
able hydrogels, including polyglycerol sebacate acry-
late and methacryloyl- substituted tropoelastin, have 
been shown to adhere effectively to wet tissues.52,53 
Both polyglycerol sebacate acrylate and methacryloyl- 
substituted tropoelastin can be photo–crosslinked in 
vivo with an ultraviolet light source. Because of con-
cerns about long- term risks of ultraviolet exposure, 
in vivo cross linking of polyglycerol sebacate acrylate 
and methacryloyl- substituted tropoelastin is imprac-
tical. Although ex vivo cross linking could be consid-
ered for these hydrogels, requirement that the hydrogel 
be applied as a preformed solid could limit clinical 
Figure 6. Immunofluorescent staining of short- axis sections from gelatin methacryloyl (GelMA)–
treated and untreated mice.
Representative images of immunofluorescent staining of untreated and GelMA- treated hearts against 
sarcomeric α-actinin (SAA) (A), cardiac troponin I (cTnI) (B), connexin 43 (Cx43) (C), CD31 (D), CD3 (E), and 
CD68 (F). Samples were counterstained with 4′, 6- diamidino- 2- phenylindole (DAPI). Red arrows indicate 
the area of the left ventricle (LV) affected by the ligation of the anterior interventricular artery leading to 
myocardial infarction.
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applications. Because of the known disadvantages of 
ultraviolet cross linking, in vivo comparisons between 
GelMA bioadhesive and ultraviolet- requiring hydrogel 
systems were not performed as part of this study.
The GelMA bioadhesive hydrogel described in this 
study was designed to address the limitations asso-
ciated with previously reported hydrogels and adhe-
sives. In this study, GelMA was demonstrated to be 
nontoxic, biocompatible (Figure  1F), and biodegrad-
able (Figure 1D). The concentration of GelMA precur-
sors and the duration of cross linking time were “tuned” 
to produce a bioadhesive that would maintain struc-
tural integrity for at least 14 days after cross linking. This 
time period was selected to provide structural support 
(and possibly deliver drug or cell therapies) during the 
post- MI healing period (Figure 1D).53 GelMA was rap-
idly and efficiently photo–cross linked in vitro using a 
visible- spectrum light source (Figure 1B).
The elastic modulus of cross linked GelMA bioad-
hesive can also be “tuned” to match a target tissue. 
A previously described GelMA formulation was pro-
duced to have an elastic modulus that matches that 
of lung.54 This previous version of GelMA, which was 
photo–cross linked using an ultraviolet light source, 
used a 20% (w/v) polymer concentration. The GelMA 
formulation in the current study used a 10% (w/v) poly-
mer concentration and produced a cross linked bioad-
hesive whose elastic modulus was comparable to that 
of native mouse myocardium (Figure 1C).
The GelMA formulation described in this study also 
adheres strongly to the epicardial surface of the heart 
(Figure 2). Adhesion of GelMA to wet tissue was stron-
ger than the adhesion reported for other adhesives, 
including the commercially available surgical sealant 
Coseal.36 The strong adhesion of the scaffold to the 
tissue could be partly explained by the molecular en-
tanglement between the hydrogel polymer chains 
and extracellular matrix proteins.36 Infiltration of the 
extracellular matrix by the liquid GelMA bioadhesive 
precursor before cross linking may also contribute to 
the strength of adhesion.55 A previously reported for-
mulation of GelMA used as an injectable hydrogel has 
been studied in the context of an infarct model.26 This 
older version of GelMA was not designed to adhere to 
tissue and was therefore delivered via intramyocardial 
injection. Placement of the bioadhesive on the epicar-
dial surface, where light exposure can be consistently 
controlled, facilitates more precise control over the 
photo–cross linking process. This is thought to lead to 
formation of a stronger scaffold and stronger scaffold- 
tissue cross linking.
On the basis of these in vitro and ex vivo data, we 
hypothesized that GelMA bioadhesive could be suc-
cessfully photo–cross linked to injured myocardium 
in the context of a mouse model of MI (Figure  3). 
Epicardial application of GelMA bioadhesive had no 
impact on intraprocedural mortality during experimen-
tal MI (Table  1) and was associated with significantly 
lower mortality during the 3- week observation period 
after MI (Table 1). Postmortem inspection of mice that 
did not survive the 3- week monitoring period revealed 
evidence that LV rupture was the cause of death. It is 
therefore likely that GelMA treatment reduced post- MI 
mortality by preventing LV free wall rupture. In addition, 
GelMA- treated mice that survived the 3- week moni-
toring period exhibited improved LV function (Figure 4, 
Table 2) and reduced scar burden (Figure 5), compared 
with untreated mice.
Immunostaining confirmed that GelMA treatment 
reduced scar burden and disruption of LV architecture 
following MI (Figure 6A through 6C). Epicardial applica-
tion of GelMA led to the preservation of CMs in the in-
farcted tissue without an observed increase in infiltration 
of macrophages or other evidence of inflammation in the 
infarcted territory (Figure 6E and 6F). Preservation of CMs 
and myocardial integrity in the infarcted territory is thought 
to be responsible for the improvement of LV systolic func-
tion following GelMA treatment. In other animal models, 
hydrogels containing a different version of GelMA and/
or extracellular matrix proteins were shown to reduce 
post-MI scar burden and improve LV function.56,57 Use of 
an extracellular matrix-based hydrogel in humans after MI 
resulted in improved ventricular function.58
Previously reported data suggest that the physi-
cal reinforcement provided by hydrogel scaffolds may 
not be sufficient to prevent negative remodeling after 
MI.13,59 The data in this study expand on the observed 
improvement in LV function associated with intravas-
cular delivery of fibrin- based nanogels in a mouse 
model of MI.60 The reduced scar burden observed with 
epicardial GelMA application after MI suggests that 
GelMA may generate a biomimetic scaffold. Although 
GelMA was shown to be biocompatible with several 
cardiac cell types (CMs and CFs) in vitro, further stud-
ies will be required to assess endogenous cell growth 
with epicardial GelMA application in vivo.
CONCLUSIONS
We concluded that the visible light cross linked GelMA 
system described in this study constitutes a rapid and 
controlled strategy to deliver a supportive scaffold to 
the site of myocardial injury. The magnitude of the effect 
observed in this study suggests that GelMA may be a 
useful system for the future study of molecular signals 
in the post- MI injury response. It is anticipated that this 
biocompatible, biodegradable hydrogel will ultimately 
be capable of being delivered percutaneously using 
a map- guided system for epicardial injection. In addi-
tion, the GelMA system used in this study was designed 
to maintain structural integrity for 14 days after cross-
linking to both provide mechanical support and, in the 
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future, provide a platform for the delivery of drug or cell 
therapies.
Limitations
The experimental infarct model involved permanent 
coronary artery ligation. Therefore, the observed re-
sults may not be generalizable to other models of myo-
cardial injury, such as ischemia- reperfusion. Additional 
studies will be required to determine whether the 
GelMA hydrogel formulation can facilitate endogenous 
cell proliferation, the sustained delivery of therapeutic 
agents (eg, drugs, cells) to injured myocardium, or both 
with the aim of preserving or restoring normal cardiac 
function following MI.
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